Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients

Circulating Tumor DNA Clinical Trial

Official title: Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients

Status Not yet recruiting

Clinical Trial Summary

Verify the Coincidence rate between Circulating tumor cells (CTCs) and tumor tissue or Circulating tumor DNA (ctDNA) of advanced NSCLC patients with Driver gene mutation

Clinical Trial Description

1. Enrich CTCs from advanced Non-Small Cell Lung Cancer (NSCLC) patients with Driver gene mutation, and detect the Epidermal Growth Factor Receptor (EGFR) mutation, Anaplastic lymphoma kinase (ALK) fusion, ROS proto-oncogene receptor tyrosine kinase 1 (ROS1) fusion, RET proto-oncogene (RET) fusion and Mesenchymal-Epithelial Transition factor (MET) 14 exon skipping by Lung cancer Polymerase Chain Reaction (PCR) panel kit, and verify the mutation coincidence rate between CTCs and tumor tissue.

2. Enrich ctDNA from advanced NSCLC patients with Driver gene mutation, detect the EGFR mutation by PCR, and detect the ALK fusion, ROS1 fusion, RET fusion and MET 14 exon skipping by next generation sequencing (NGS), and compare the mutation coincidence rate between CTCs and ctDNA. ;

Related Conditions & MeSH terms

• Advanced NSCLC
• Circulating Tumor Cells
• Circulating Tumor DNA
• Neoplasms
• Neoplastic Cells, Circulating

• NCT number: NCT04229121
• Study type: Observational
• Source: Shanghai Pulmonary Hospital, Shanghai, China
• Contact: Yayi He, MD,PHD
• Phone: +862165115006
• Email: 2250601@qq.com
• Status: Not yet recruiting
• Start date: January 15, 2020
• Completion date: December 15, 2020